Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib-Reference-Cited by-同舟云学术

Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib

Published:2016-12-16 Issue:3 Volume:57 Page:539-543
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Marotta Vincenzo,Sciammarella Concetta,Capasso Mario,Testori Alessandro,Pivonello Claudia,Chiofalo Maria Grazia,Pivonello Rosario,Pezzullo Luciano,Botti Gerardo,Colao Annamaria,Faggiano Antongiulio

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s12020-016-1200-6/fulltext.html

Reference33 articles.

1. V. Marotta, C. Sciammarella, M. Vitale, A. Colao, A. Faggiano, The evolving field of kinase inhibitors in thyroid cancer. Crit. Rev. Oncol. Hematol. 93(1), 60–73 (2015). doi: 10.1016/j.critrevonc.2014.08.007

2. S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52(2), 214–221 (2016). doi: 10.1007/s12020-015-0830-4

3. M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Pena, I. Molnar, M.J. Schlumberger: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. (2014). doi: 10.1016/S0140-6736(14)60421-9 .

4. M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015). doi: 10.1056/NEJMoa1406470

5. V. Marotta, V. Ramundo, L. Camera, M. Del Prete, R. Fonti, R. Esposito, G. Palmieri, M. Salvatore, M. Vitale, A. Colao, A. Faggiano, Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin. Endocrinol. (Oxf). 78(5), 760–767 (2013). doi: 10.1111/cen.12057

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy;Drug Resistance Updates;2023-05

2. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension;International Journal of Molecular Sciences;2021-11-12

3. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale;Frontiers in Endocrinology;2021-08-12

4. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer;Journal of Personalized Medicine;2021-07-18

5. Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter;Journal of Endocrinological Investigation;2019-08-02